Critical Warnings & Restrictions In Canada

Basic Daxas Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In Canada (English): Glucophage, Glumetza, generic
• ATC Code: A10BA02
• Forms & Dosages: Immediate-release tablets 250mg, 500mg, 850mg, 1000mg; extended-release tablets 500mg, 750mg, 1000mg; oral solution 500mg/5mL
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries; not available as OTC

Are you worried about serious side effects or whether Daxas is safe for someone you care about?

Stop and read this checklist first before starting or continuing Daxas (roflumilast).

• Highest risks to watch: new or worsening psychiatric symptoms including insomnia, anxiety, depression, or suicidal thoughts.
• Significant weight loss: clinically important weight loss should prompt reassessment and close follow-up.
• Hepatic impairment: avoid or do not start Daxas in moderate–severe liver disease.
• Indication reminder: Daxas is an adjunct for severe COPD with chronic bronchitis and frequent exacerbations, not a rescue inhaler for acute bronchospasm.

High-risk groups need extra caution and baseline screening.

• Elderly: increased comorbidities and polypharmacy raise the risk of drug interactions and neuropsychiatric effects.
• Pregnant or breastfeeding people: avoid unless benefits clearly outweigh risks and specialist input is available.
• Indigenous health considerations: watch for access barriers, cultural safety needs, and higher prevalence of comorbid conditions.

Workplace guidance for safety-sensitive roles.

• Dizziness, impaired concentration, severe insomnia or mood changes can affect driving and operation of heavy machinery.
• Employers and patients should consult provincial occupational health standards where relevant.
• Document informed consent and provide culturally safe counselling for Indigenous patients.

Immediate action steps.

• Stop the drug and seek urgent care for suicidal thoughts, severe weight loss (>5% body weight), or signs of liver injury (jaundice, dark urine, severe abdominal pain).
• Report new psychiatric symptoms immediately to the prescriber and pharmacist.
• Arrange mood monitoring and liver function testing as recommended before and during therapy.

High-Risk Groups

Elderly patients frequently have multiple medicines and chronic conditions that increase the chance of interactions with roflumilast.

Pregnant or breastfeeding people should consult obstetric care—data are insufficient to support routine use.

Indigenous patients may face access barriers and culturally specific health priorities that require respectful, documented informed consent and community supports.

Interaction With Activities

Dizziness, drowsiness, impaired concentration, visual disturbance, severe insomnia, or acute mood changes on Daxas can impair driving and machine operation.

Provincial workplace safety rules may require disclosure or temporary reassignment for safety-sensitive tasks.

Q&A — “Can I Drive After Taking It In Canada?”

• If you experience dizziness, drowsiness, impaired concentration, visual disturbance, severe insomnia, or mood changes on Daxas, do not drive or operate machinery.
• Report new psychiatric symptoms immediately to your prescriber.
• If you have none of these effects, the medication alone is not an automatic legal restriction, but employers or provincial workplace safety policies may require disclosure for safety-sensitive roles.

Usage Basics For Canadians

INN, Brand Names Available In Canada

Daxas is the trade name commonly used for roflumilast in many markets and is known as Daliresp in some international listings.

In Canada, roflumilast products are prescription-only and will appear under the active name roflumilast or a brand name such as Daxas or Daliresp where marketed.

At dispensing, expect counselling that covers indication, dosing, expected timeline for effect, and side-effect monitoring.

Legal Classification Under Health Canada

• Roflumilast is prescription-only in Canada and requires a valid prescription and a Drug Identification Number (DIN) for supply and reimbursement.
• Patients typically need specialist assessment (pulmonologist or respirologist) for prior-authority applications to provincial formularies.
• Pharmacists should provide counselling on indication, dosing (500 mcg once daily), and that Daxas is not for relief of acute bronchospasm.

Canadian Dosing Guide

Standard Regimens

The usual adult dose is 500 mcg once daily taken orally at the same time each day.

Daxas is not indicated for children and is not intended for immediate relief of acute bronchospasm.

• Baseline checks before starting should include weight/BMI, liver function tests (ALT/AST, bilirubin), mood screening, and complete medication review.
• Assess interactions with CYP3A4 and CYP1A2 inducers or inhibitors such as rifampin, carbamazepine, phenytoin, and erythromycin/clarithromycin.

Adjustments For Comorbidities

Avoid initiation in moderate–severe hepatic impairment and exercise caution in patients with low BMI or cachexia because weight loss is a common adverse outcome.

No routine renal dose adjustment is required in mild-to-moderate renal impairment, but use caution in patients with severe comorbidities and monitor closely.

Screen for diabetes and other common comorbidities in the Canadian population as part of comprehensive care.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

• If you miss a single dose, take it as soon as you remember unless it is nearly time for the next dose—do not double up.
• Provincial coverage rules do not change clinical missed-dose advice; they may limit refill timing or require prior authorization so plan refills early.
• If coverage interruption occurs, consult your pharmacy for emergency supply options and the prescriber for bridging prescriptions.

Interaction Chart (Canadian Context)

Food And Drinks

Alcohol misuse increases the risk of liver injury and weight loss while taking roflumilast and should be limited.

Caffeine does not have a pharmacokinetic interaction, but coffee or other stimulants may worsen insomnia for susceptible patients.

Common Drug Conflicts

• During medication reconciliation, look for interacting drugs commonly used by older Canadians.
• Pharmacists should review interactions at each fill and document counselling.
• Refer to Health Canada advisories for the most up-to-date interaction listings.

User Reports & Trends In Canada

Canadian Patient Forums And Review Platforms

Patients often report fewer COPD exacerbations after several months on roflumilast when combined with optimized inhaled therapy.

Commonly reported harms include weight loss, gastrointestinal upset, insomnia, and mood changes leading some to discontinue therapy.

Community Pharmacy Feedback

• Pharmacists note adherence problems related to neuropsychiatric side effects and weight loss monitoring requirements.
• Some patients experience clear benefit and reduced need for oral steroids or antibiotics over time.
• Encourage anonymous patient-reported outcome measures during clinic visits and report adverse events to Canada Vigilance.

Access & Purchase Options

National Pharmacy Chains

Daxas and generic roflumilast may be obtained through major retail pharmacies such as Shoppers Drug Mart, Rexall, London Drugs, and Jean Coutu where available with a prescription.

Many provincial formularies require prior authorization or specialist confirmation for coverage.

Online Pharmacies In Canada & Provincial Restrictions

• Purchase checklist: valid prescription, pharmacist counselling, prior authorization paperwork if needed, confirm DIN and brand/generic substitution rules.
• Do not import from unlicensed sources because of legal and safety risks; use licensed Canadian pharmacies only.
• In our online pharmacy, daxas is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

Roflumilast is an oral phosphodiesterase‑4 (PDE4) inhibitor that reduces lung inflammation by increasing intracellular cAMP and lowering inflammatory mediator release.

It is used to reduce the frequency of exacerbations in patients with severe COPD and chronic bronchitis.

Because it is not a bronchodilator, it does not replace inhaled rescue medication for acute breathlessness.

Clinical Terms

• Onset of benefit may take weeks to months and is measured by reduced exacerbation frequency rather than immediate lung relief.
• Metabolism: hepatic CYP pathways (CYP3A4 and CYP1A2) produce an active metabolite; interactions with inducers and inhibitors are clinically important.
• References: consult Health Canada monograph and product-specific DIN monographs for full pharmacology.

Indications & Off-Label Uses In Canada

Approved Indications (DIN)

Health Canada–approved indication: adjunctive therapy to reduce exacerbations in severe COPD associated with chronic bronchitis and a history of frequent exacerbations despite long-acting bronchodilator therapy.

Common Off-Label Practices (Canadian Physicians)

Off-label use is limited and typically confined to research contexts or specialist-directed trials for related inflammatory airway conditions, not routine clinical practice.

Real Data Block (comparative reference supplied): INN Metformin; Canadian brand names Glucophage, Glumetza, generic; ATC A10BA02; common strengths 500mg, 850mg, 1000mg; renal contraindication eGFR <30 mL/min/1.73m².

Key Clinical Findings

Canadian And International Studies 2022–2025

• Randomized trials show roflumilast reduces moderate-to-severe COPD exacerbations in chronic bronchitis phenotype with prior exacerbation history.
• Improvements in FEV1 are modest and benefit is mostly in exacerbation reduction rather than bronchodilation.
• Tolerability signals include higher discontinuation rates due to weight loss and neuropsychiatric events.
• Recent observational cohorts and pharmacovigilance data (2022–2025) highlight psychiatric events and sustained weight loss as monitoring priorities.

Ongoing Health Canada Safety Monitoring

Serious psychiatric or hepatic events should be reported to Canada Vigilance by clinicians and patients to support post-marketing safety surveillance.

Prescribers should document baseline assessments and ongoing monitoring plans in the chart.

Alternatives Matrix

Comparable Medicines With DIN In Canada

Pros And Cons Checklist

• Pros of Roflumilast: oral dosing, additive reduction in exacerbations for the right phenotype.
• Cons: systemic side effects (weight loss, psychiatric risk), need for liver and mood monitoring, drug interactions.
• Selection checklist: phenotype (chronic bronchitis vs emphysema), exacerbation frequency, inhaler optimisation, psychiatric/hepatic comorbidity, patient preference.

Common Questions From Canadian Patients

• How quickly will it work? Benefits for exacerbation reduction usually appear over weeks to months, not immediately.
• Will it replace inhalers? No; roflumilast is an adjunct and does not replace inhaled bronchodilators or rescue inhalers.
• What side effects are most likely? Gastrointestinal upset, weight loss, insomnia, and mood changes are the most commonly reported tolerability concerns.
• What monitoring is needed? Baseline and periodic weight checks, liver function tests, and mood screening—early follow-up at 4–6 weeks is recommended.
• Can pregnant or breastfeeding people use it? Data are insufficient; avoid use unless specialist advises otherwise.
• Contact provincial telehealth or your local pharmacist immediately for urgent concerns and report adverse effects to Canada Vigilance.
• Request language supports and culturally safe discussion when working with Indigenous patients or francophone communities in Quebec.

Coverage & Purchase Comparison Table

Province/Plan Coverage Snapshot

Step-By-Step Purchase Checklist For Canadian Patients

1. Obtain a specialist prescription (pulmonologist/respirologist advisable).
2. Request prior authorization paperwork from prescriber if your province requires it.
3. Present spirometry and exacerbation history to the pharmacist for formularies.
4. Confirm DIN, brand/generic substitution rules, and estimated patient cost.
5. Plan monitoring visits and how reports will be shared among care providers.

Registration & Regulation

Health Canada Approval

• Roflumilast products are regulated and must have an assigned Drug Identification Number (DIN) for marketed products.
• Pharmaceutical labelling must meet Canadian requirements, including bilingual labelling where applicable.
• Clinicians and pharmacists are required to supply patient medication information and report adverse reactions.

DIN Number And Labelling Requirements

Each product/strength will have a specific DIN and bilingual labels where required by provincial rules.

Consult Health Canada’s Drug Product Database for the current DINs and product monographs.

Storage & Handling

Standard Canadian Household Conditions

Store roflumilast at room temperature, below 25°C, in the original packaging and away from direct sunlight and moisture.

Do not refrigerate or freeze standard tablets.

Cold-Chain Requirements

• Do not flush unused medication; return to pharmacy take-back programs for safe disposal.
• Pharmacies should counsel on clear labelling and safe storage, especially for remote and Indigenous communities.

Guidelines For Proper Use

Canadian Pharmacist Guidance

1. Confirm indication with spirometry and ensure inhaler optimisation before considering roflumilast.
2. Screen for psychiatric history and hepatic impairment; obtain baseline LFTs and weight.
3. Review full medication list for CYP3A4 and CYP1A2 inducers/inhibitors and antidepressant interactions.
4. Initiate at 500 mcg once daily with a clear mood and weight monitoring plan and an early follow-up at 4–6 weeks.
5. Document informed consent and provide culturally safe counselling for Indigenous patients when appropriate.

Provincial Health Authority Recommendations

• Follow the Canadian Thoracic Society COPD guidelines for stepwise escalation of therapy and documentation for formulary coverage.
• Coordinate care between specialists, primary care, and community pharmacists for monitoring and adverse-event reporting.
• Use provincial telehealth and COPD support groups to improve follow-up in remote regions.

Delivery Across Canada (English)

Final Notes For Patients And Clinicians

When counselling patients, emphasise that roflumilast (Daxas) is intended to reduce exacerbation frequency and is not a rescue inhaler.

Document baseline weight and LFTs, screen mood at start and at 4–6 weeks, and keep a low threshold for stopping the drug if psychiatric symptoms or significant weight loss occur.

Report serious adverse events to Canada Vigilance and involve specialist input where there is hepatic disease or complex polypharmacy.

For any questions about coverage, prior authorization paperwork, or an emergency supply during a coverage gap, contact your pharmacy for assistance and pharmacist counselling.